Adult Still Disease (AOSD): Symptoms, Treatment & When to Seek Care

Adult‑onset Still disease conceptualises the spectrum of systemic autoinflammatory pathology that begins after adolescence but reproduces the phenotype long recognised in systemic juvenile idiopathic arthritis: unrelenting myeloid activation with IL‑1 and IL‑6 axis exaggeration producing daily fevers, skin microvascular leakage patterns, serosal irritation, and cytokine-responsive arthritis. Nurses translate that bench language into ward reality—patients oscillate between flares that feel infective and brittle post-inflammatory states when immunosuppression deepens.

Because no single assay definitively stamps the diagnosis, rheumatology teams weave clinical criteria, supportive laboratory signatures, and prudent exclusion of pathogens and lymphoma mimicry. Chronic articular patterns may overlap RA phenotype but seronegativity and explosive systemic features usually redirect thought away from classic autoantibody-mediated disease.

Yamaguchi criteria remain a frequently taught framework: five major domains (fever, arthralgia/arthritis, erythematous rash, leukocytosis ≥10×10⁹/L, hepatomegaly/splenomegaly/lymphadenopathy) plus minor clues (sore throat, abnormal LFTs, negative ANA & RF) support classification when infection and malignancy exclusions hold. Diagnosis classically requires ≥5 features with ≥2 majors—verify against the active institutional derivative your rheumatologists cite because international sets (Fautrel, Yamaguchi) differ on weighting.

↔On a small screen, swipe or scroll sideways to see the full table.

Pattern tables describe teaching emphasis—individual patients violate textbook ratios; escalate on clinical instability, not ferritin logarithms alone.

Inflammation rarely whispers quietly: wards meet patients with towering high fever curves, symmetrical muscle soreness, and evocative rash–temperature coupling best witnessed during thermometer peaks—ask caregivers to describe whether maculopapular rash vanishes between spikes.

Characteristic features

• Quotidian (often evening-predominant) temperature surges disproportionate to culture data once appropriate sampling completes.
• Pharyngitic discomfort without definitive streptococcal centrifuge—coordinate throat swab stewardship before blanket antibiotics obscure cultures.
• Inflammatory joint pain migrating from wrists and knees outward; effusions may fluctuate briskly.
• Diffuse myalgias and fatigue resembling viral syndromes but persisting beyond expected recovery windows.

Atypical or subtle variants

• Hepatic predominant flares dominating with jaundice—obstructive pathology still requires imaging triage.
• Fever-of-unknown-origin phenotype before rash prominence—maintain serial skin checks during thermometer handling.
• Overlap with macrophage physiology masquerading as isolated coagulopathy—never normalise unexplained INR drift.

Environmental triggers debated in literature include encapsulated viral exposures and Yersinia/Mycoplasma species—interesting academically yet rarely change bed-level management except when travel or outbreak history demands directed cultures. Medication triggers (rash-fever drug reaction) remain on every differential until reconciled.

Modifiable vs contextual factors

• Modifiable: judicious NSAID exposure if renal or GI risk; structured physiotherapy maintaining joint range without overtraining through active fever.
• Non-modifiable: age window peak in young adults, female slight predominance in some cohorts, genetic loading.

Clinical assessment

Pattern recognition begins with fever–rash–arthralgia triad plus objective systemic inflammation; document temperature curve shape, joint counts, and mucocutaneous evolution across shifts to give consultants longitudinal texture.

Laboratory investigations

• CBC with differential leucocytosis tracking; abrupt decline flags MAS.
• CRP plus ESR for inflammatory kinetics.
• Ferritin serial trending—contextual not pathognomonic.
• ANA, RF, anti-CCP negativity supports separation from SLE-like or RA-like disease yet does not exclude overlap—see rheumatology-aligned pages on systemic lupus erythematosus and rheumatoid arthritis for phenotype contrast.

Imaging

Ultrasound or MRI documents synovitis when joints appear misleadingly quiet on inspection; chest imaging follows pleuritic symptoms or hypoxia.

Diagnostic criteria / scoring

Apply Yamaguchi (or updated composite criteria your service prefers) only after targeted infection and malignancy screening—coordinate blood culture draws before antibiotics when safe, imaging or marrow strategy per hematology if lymphoproliferative features surface.

1. Detect: flag quotidian fever + evanescent rash + inflammatory joints in young adult after reasonable infection work-up stalls.
2. Monitor: schedule laboratory recheck cadence (often 24–48 h during induction) per team—trend ferritin, CBC, LFTs, coagulation.
3. Threshold → action: rising oxygen requirement, encephalopathy, or falling counts trigger MAS bundle activation.
4. Refer: rheumatology within days for new diagnosis; earlier if eye, cardiac, or liver involvement.
5. Escalate: ICU criteria if shock, refractory hypoxia, or multi-organ failure supervenes—communicate corticosteroid timing and last biologic dose.

↔On a small screen, swipe or scroll sideways to see the full table.

Therapy intensity tracks organ threat and articular destruction risk—decisions stay prescriber-led; nursing ensures monitoring logistics keep pace with immunosuppression depth.

First-line

• High-dose NSAID class for mild systemic disease without contraindications—watch renal function and GI bleeding sentinels.
• Oral or IV glucocorticoids for moderate–severe flares; pulse methylprednisolone during catastrophic inflammation per protocol.

Second-line / steroid-sparing

• Methotrexate DMARD backbone for chronic articular disease—folic acid and LFT surveillance per pharmacy grid.
• IL‑1 blockade (e.g. anakinra) commissioned under NHS NICE TA685 after inadequate response to two conventional DMARDs in eligible adults—pre-biologic infection screening mandatory.
• IL‑6 receptor blockade (tocilizumab class) appears in contemporary international treatment reviews as alternative cytokine pathway strategy—align with local formulary.

Special populations

• Pregnancy: MTX contraindicated; biologic teratogenicity counselling requires maternal–fetal medicine partnership.
• Renal/hepatic impairment: dose-adjust NSAIDs, vigilance for methotrexate accumulation, monitor biologic clearance guidance.

• Monitoring intervals: daily or alternate-day labs during induction flares; extend toward weekly once stable per team.
• Escalation triggers: new oxygen requirement, MAP trends, coagulopathy, confusion—activate hospital emergency response per policy.
• Referral: rheumatology + hematology joint clinics for MAS suspicion; infectious diseases if atypical culture data.
• MDT roles: pharmacists titrate interaction checks (MTX + trimethoprim etc.); physio maintains safe mobilisation while febrile.

• Macrophage activation syndrome—mortality driver if treatment delayed.
• Diffuse alveolar haemorrhage / ARDS pattern in fulminant cytokine storm case series.
• Chronic destructive arthritis when inflammation smoulders—mirrors RA-like joint damage (compare structural progression discussion on specialised arthritis pages).
• Amyloidosis in decades-long disease—proteinuria surveillance when rheumatology requests.

Clinician-facing prevention emphasises infection-proximate vigilance when biologics deploy, vaccination catch-up where guidelines allow, osteoporosis mitigation around chronic glucocorticoids, and structured medication education so patients recognise early MAS symptoms between appointments.

Approximately one-third monophasic, one-third polyphasic, one-third chronic articular courses appears in modern clinic descriptions—individual trajectories vary; nursing documentation of flare frequency informs realistic counselling about employment and functional planning.

Ward morale improves when bedside staff narrate the autoinflammatory story consistently—patients labelled “culture-negative sepsis” without closure feel dismissed; reinforcing honest uncertainty while maintaining safety netting reduces conflict.

• Chart every biologic dose, lot, infusion reaction, and steroid taper instruction—oncology-grade precision prevents contradictory orders.
• Screen visitors for infectious symptoms when neutropenia or high-dose steroids coincide.

• Vitals—including orthostasis after steroid weans.
• Skin pattern photography consent when feasible.
• Strict fluid balance during capillary leak physiology.
• Neuro checks if new headache or cognition shift during cytopenia.

Objective cues for senior notification include widening pulse pressure variation, lactate trending, fibrinogen free-fall despite CRP plateau, ICU-ready mental status changes, and inability to maintain enteral steroids due to vomiting—pre-brief these thresholds at handover.

Pre-biologic / acute flare

• Verify infection screens complete; hold live vaccines per policy.
• Educate on injection-site rotation for subcutaneous IL‑1 agents when applicable.

During glucocorticoid taper

• Monitor glucose, mood, sleep, and bone pain—flag steroid withdrawal mimic vs true flare.

Evaluation

• Use standardised pain and fatigue scores each shift to objectify subjective cytokine malaise.

These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, deterioration trends, multi-patient triage, ordered response, matrix matching and cloze drops on the topic of adult-onset Still’s disease (quotidian fevers, salmon-pink rash, arthritis, ferritin >5× ULN), macrophage activation syndrome and the IL-1 / IL-6 inhibitor ladder.